An Increase in Mental Stress due to Hectic Life and Unhealthy Habits Drive the Demand for Sleep Disorder Treatment Market

With the growing age, the prevalence of the sleep disorder is also rising, increasing the demand for several treatment for sleep disorders such as narcolepsy, sleep apnea, and restless legs syndrome, among others. Furthermore, the pressure on the healthcare system is growing with the increasing population. The demand for services, care and technologies is also surging to prevent and treat sleep disorders leading to mental health problems.

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-sleep-disorder-treatment-market

Data Bridge Market Research analyses that the sleep disorder treatment market is expected to reach USD 18419.97 million by 2030 from USD 9312.49 million in 2022, growing with a healthy CAGR of 8.90% in the forecast period of 2023 to 2030. The increase in mental stress is observed owing to the hectic lifestyle lived by the individuals who neglect the value of their health. The busy working life and mismanaged lifestyle of people are increasing stress levels and leading to several sleep disorders globally. These factors are expected to provide potential opportunities for market growth in the forecast period.

Sleep Disorder Treatment Market

The increasing prevalence of sleeping disorders is expected to drive the market's growth rate

Sleep disorders are also called somnipathy. It contains several medical situations that negatively influence a person's sleeping pattern. Sleep disorders can also be well-defined as a group of disorders which is impacting sleep pattern of an individual on a regular basis. Several factors are responsible for the disorders, including high stress and lifestyle changes. The sleep disorders impact the overall health, affecting the level of concentration and leading to a person's tiredness throughout the day. Sleep apnea, narcolepsy, insomnia, sleep walking and restless leg syndrome (RLS) are some of the common sleep disorders observed all over the globe. The rapidly changing lifestyle, increased use of social media and growing adoption of gadgets are increasing the prevalence of sleeping disorders across several regions in the globe.

 Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2021

Historic Years

2020 (Customizable to 2015 - 2020)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Type (Insomnia, Sleep Apnea, Restless Legs Syndrome (RLS), Narcolepsy and Others), Treatment (Pharmacological Therapy, Mechanical Therapy, Mandibular Advancement Devices, Hypoglossal Nerve Stimulator, Surgery and Others) Route of Administration (Oral, Parenteral and Others), Drugs Type (Branded and Generics), Population Type (Children and Adults), End User (Hospitals, Specialty Clinics, Home Healthcare, Ambulatory Surgical Center and Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Others)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Market Players Covered

Jazz Pharmaceuticals, Inc. (Ireland), Pfizer Inc. (U.S.), Viatris Inc. (U.S.), Arbor Pharmaceuticals Inc. (U.S.), Aurobindo Pharma USA (U.S.), Sanofi (U.S.),  Hikma Pharmaceuticals PLC (U.K.), Amneal Pharmaceuticals LLC (U.S.), Lupin Pharmaceuticals, Inc. (India), Taj Pharmaceuticals Limited (India), Eli Lilly and Company (U.S.), Mallinckrodt (U.K.), Alembic Pharmaceuticals Limited (India), Apotex Inc. (Canada), Dr. Reddy's Laboratories Ltd. (India), Teva Pharmaceuticals Industries Ltd. (India), Taro Pharmaceutical Industries Ltd. (U.S.), DeVilbiss Healthcare LLC (U.S.), ResMed (U.S.)

Data Points Covered in the Report

In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Segment Analysis:

The sleep disorder treatment market is segmented on the basis of type, treatment, route of administration, drugs type, population type, end user and distribution channel.

  • On the basis of type, the sleep disorder treatment market is segmented into insomnia, sleep Apnea, restless legs syndrome (RLS), narcolepsy and others. In 2022, insomnia segment is dominating the market and is growing with the highest CAGR of 9.10% in the forecast period of 2023 to 2030 due to augmented pipeline products for the cure of the sleep disorders by major market players.
  • On the basis of treatment, the sleep disorder treatment market is segmented into pharmacological therapy, mechanical therapy, mandibular advancement devices, hypoglossal nerve stimulator, surgery and others.

In 2022, the pharmacological therapy segment of treatment segment is anticipated to dominate the sleep disorder treatment market

Pharmacological therapy segment is dominating the market and is growing with the highest CAGR of 10.00% in the forecast period of 2023 to 2030 because of the safe and economical form of administration leading to augmented uptake by the suffered patients.

  • On the basis of route of administration, the sleep disorder treatment market is segmented into oral, parenteral and others. In 2022, oral segment is dominating the market and is growing with the highest CAGR of 9.10% in the forecast period of 2023 to 2030 because of the easy availability and economical nature of the generics drugs for the treatment of the sleep disorder.
  • On the basis of drugs type, the sleep disorder treatment market is segmented into branded and generics.

In 2022, the generics segment of drugs type segment is anticipated to dominate the sleep disorder treatment market

Generics segment is dominating the market and is growing with the highest CAGR of 9.30% in the forecast period of 2023 to 2030 due to the presence of the U.S. FDA approved pharmacological therapies for the cure of sleep disorder in adults

  • On the basis of population type, the sleep disorder treatment market is segmented into children and adults. In 2021, adults segment is dominating the market and is growing with the highest CAGR of 9.10% in the forecast period of 2023 to 2030 because hospitals are the main location visited by patients for any surgery or procedure.
  • On the basis of end user, the sleep disorder treatment market is segmented into hospitals, specialty clinics, home healthcare, ambulatory surgical center and others. In 2021, hospitals segment is dominating the market and is growing with the highest CAGR of 9.20% in the forecast period of 2023 to 2030 because direct tender fulfils the requirement of patients and physicians.
  • On the basis of distribution channel, the sleep disorder treatment market is segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy and others. In 2021, direct tender segment is dominating the market and is growing with the highest CAGR of 9.5% in the forecast period of 2023 to 2030 because most of the facilities procure from direct tenders.

Major Players

Data Bridge Market Research recognizes the following companies as the major sleep disorder treatment market players in sleep disorder treatment market Jazz Pharmaceuticals, Inc. (Ireland), Pfizer Inc. (U.S.), Viatris Inc. (U.S.), Arbor Pharmaceuticals Inc. (U.S.), Aurobindo Pharma USA (U.S.), Sanofi (U.S.), Hikma Pharmaceuticals PLC (U.K.), Amneal Pharmaceuticals LLC (U.S.), Lupin Pharmaceuticals, Inc. (India), Taj Pharmaceuticals Limited (India), Eli Lilly and Company (U.S.),

Sleep Disorder Treatment Market

Market Development

  • In July 2020, Jazz Pharmaceuticals plc announced the FDA approval for its new drug named Xyway for the sign of both excessive daytime sleepiness and cataplexy in people living with narcolepsy for the age group of more than 15 years. This new sleep disorder therapeutic has been approved by the U.S. FDA. As a result, it has augmented the demand and sales for its drug in the market, leading to increased revenue in the upcoming period.

Regional Analysis

Geographically, the countries covered in the sleep disorder treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America..

As per Data Bridge Market Research analysis:

North America is the dominant region in sleep disorder treatment market during the forecast period 2023 to 2030

North America dominates the sleep disorder treatment market due to increasing demand for sleep disorder treatment in Canada and United States. The increase in awareness, growing prevalence of sleep disorders and high healthcare spending are expected to drive the growth of the market. Furthermore, strong clinical pipeline, favorable reimbursement policies for therapeutic products and increasing stress level are other factors which will projected to promote revenue growth.

Asia-Pacific is estimated to be the fastest-growing region in sleep disorder treatment market the forecast period 2023 to 2030

Asia-Pacific is expected to grow from 2023 to 2030 due to increased stress level and shift-work sleep disorder. These aspects may contribute to the increasing demand for drugs in these economies. Continuously improving healthcare reimbursement policies are projected to increase demand for the sleep disorder treatment. Furthermore, growing living standards spurred the regional demand. All these factors are projected to increase the regional market growth in the upcoming years.

For more detailed information about sleep disorder treatment market report, click here – https://www.databridgemarketresearch.com/reports/global-sleep-disorder-treatment-market